Table 1 Summary GHS-R expression data and statistical findings
From: Receptor of ghrelin is expressed in cutaneous neurofibromas of individuals with neurofibromatosis 1
| Â | Cutaneous Neurofibromas | Â | |
|---|---|---|---|
Large | Small | P-value | |
Mean (± standard deviation) | Mean (± standard deviation) | ||
Volume (mm3) | 1923 (±2349) | 63.9 (±62.1) | <0.0001a |
Total number of nuclei per neurofibroma | 25,878 (±10,979) | 5,2016 (±27,953) | – |
Number of positive nuclei per neurofibroma | 14,025 (±6310) | 21,912 (±14,146) | – |
Percent of positive nuclei per neurofibroma/n* | 53.6% (±9.2)/48 | 41.1%(±13.1)/48 | <0.0001b |
Percent of positive nuclei (considering the tumors of the same individuals with volume difference ≥1000 mm3)/n* | 52.9%(±8.6)/24 | 44.2%(±14.4)/24 | 0.01b |
Percent of positive nuclei (considering the tumors of the same individuals with volume difference of ≥3000 mm3)/n* | 53.6% (±8.0)/9 | 35.4% (±16.1)/9 | 0.015a |
Percent of cells with strong staining / Number of tumors with predominance of cells with strong staining | 24.1%d (±7.1)/42d | 13.5% (±9)/20 | <0.0001c |
Percent of cells with moderate staining / Number of tumors with predominance of cells with moderate staining | 17.9%d (±4.6)/13d | 13.5% (±4.3)/8 | |
Percent of cells with weak staining / Number of tumors with predominance of cells with weak staining | 11.4% (±2.7)/0 (none) | 14.1% (±4.2)/25 | |
Area of analysis (mm2) | 4.2 (±1.7) | 10.2 (±6.3) | – |